INTRODUCTION {#SEC1}
============

Accurate replication of the genome is essential for preserving cellular integrity. During the process of DNA replication, secondary structures and lesions may lead to the stalling of the replication fork ([@B1],[@B2]) and failure in dealing with such events results in genomic instability. A key component of the DNA replication and repair machineries is the replication clamp PCNA. PCNA is a homotrimeric ring that is encoded by the *POL30* gene. It slides along the DNA during replication and serves as a docking platform for polymerases and other proteins that participate in DNA replication and repair processes ([@B3]). Additionally, PCNA undergoes post-translational modifications, such as ubiquitination and SUMOylation, during normal DNA replication and upon DNA damage. These modifications have a role in directing the cell toward one of the DNA damage bypass or repair pathways \[reviewed in ([@B3])\]. Mono-ubiquitination of PCNA on lysine 164 by Rad6 and Rad18 promotes an error-prone Trans-Lesion Synthesis (TLS) repair pathway carried out by specific polymerases ([@B4]). Further poly-ubiquitination of the same residue by the E2 ubiquitin ligase Mms2/Ubc13 and the E3 ubiquitin ligase Rad5 summons an error-free damage bypass pathway that involves a transfer of information from the replicated chromatid ([@B5],[@B6]). SUMOylation of PCNA K164 and/or K127 by the SUMO ligase Siz1 enhances the binding of the Srs2 helicase, which disturbs Rad51 filament formation and thus inhibits homologous recombination (HR) ([@B7]--[@B9]).

The RFC complex, composed of a large subunit (Rfc1) and four small subunits (Rfc2--5), has the ability to load and unload PCNA onto DNA in an ATP-dependent manner ([@B10]). This activity is required at the firing of each origin of replication and for the formation of each Okazaki fragment on the lagging strand, as well as for efficient DNA repair. PCNA and its loader are essential and structurally conserved in all living organisms ([@B11]). In eukaryotic cells, three alternative clamp loaders ([R]{.ul}FC-[l]{.ul}ike [c]{.ul}omplexes or RLCs) were identified. The RLCs share the four small subunits (Rfc2--5) of the canonical Rfc1 complex, but differ in the large subunit, which share homology with Rfc1. In yeast, the three identified RLCs are Elg1, Ctf18 and Rad24. These three alternative subunits are, in contrast to Rfc1, not essential for cell viability. Nevertheless, the RLCs have important roles in maintaining genomic stability ([@B12],[@B13]). Ctf18 plays a role in sister chromatid cohesion, Rad24 is involved in the activation of the DNA damage checkpoint, and Elg1 has been implicated in many aspects of maintaining genomic stability ([@B14]--[@B16]). *ELG1* deletion results in increased sensitivity to genotoxic agents, elevated rates of spontaneous recombination, gross chromosomal rearrangements, loss of sister chromatid cohesion and elongated telomeres ([@B13]). Elg1 has been shown to interact genetically and physically with a variety of genes and proteins that are involved in DNA replication and repair, as well as with components of the SUMO pathway ([@B17]). The Elg1--RLC interacts with PCNA, particularly with its SUMOylated form, and has the ability to unload it from the chromatin ([@B18]--[@B21]). It has been recently shown that the unloading activity of the Elg1--RLC clamp is dependent on Okazaki fragment ligation ([@B21]), and that it occurs in S and G2/M phases of the cell cycle ([@B22]). The human orthologue of *ELG1*, ATAD5, has been shown to play a role in regulating the lifespan of DNA replication protein complexes by modulating PCNA levels on the chromatin ([@B23]). Homozygous ATAD5 mutations in mice are embryonically lethal, whereas over 95% of heterozygotes develop tumors. Moreover, mutations in ATAD5 were also found in several types of human cancers, implying a tumor-suppressing function for this gene ([@B24]). ATAD5 has been shown to be involved in the Fanconi Anemia DNA repair pathway by facilitating the de-ubiquitination of FANCI/FANCD2 heterodimer ([@B25],[@B26]). The yeast Elg1 interacts both genetically and physically with the yeast orthologs of the Fanconi Anemia repair pathway ([@B27]).

Although it has already been established that Elg1 is an unloader of PCNA, it is still not clear whether the phenotypes of *elg1Δ* cells are a consequence of PCNA retention on the chromatin. To address this issue, we have used homology modeling to predict the structure of Elg1, and generated various mutants that vary in their PCNA unloading ability. By examining different phenotypes of the *elg1* mutants we found that the sensitivity of *elg1* mutants to DNA damage can be correlated with their ability to unload PCNA from the chromatin, and that the various roles of Elg1 in genome stability maintenance involve the unloading of both modified and unmodified PCNA. Our results also suggest a role for the retention of mono ubiquitinated PCNA on the chromatin in the suppression of MMS sensitivity of *rad5*Δ mutants by deletion of *ELG1*.

MATERIALS AND METHODS {#SEC2}
=====================

Elg1 homology modeling {#SEC2-1}
----------------------

The Elg1 AAA+ region was modeled using similarity to the three-dimensional structure of Rfc1 from the yeast RFC--PCNA complex (PDB id: 1SXJ) ([@B10]). Elg1 and Rfc1 sequences were first aligned using pairwise comparison of corresponding profile hidden Markov models with HHsearch ([@B28]). The Elg1 structural model was then generated from the resulting sequence-structure alignment using Modeller ([@B29]). A model for Elg1 interaction with PCNA was obtained by overlaying the modeled Elg1 AAA+ region onto the Rfc1 subunit within the RFC--PCNA complex and subsequently removing the Rfc1 structure.

Yeast strains and plasmids {#SEC2-2}
--------------------------

All yeast strains used are derivatives of MK166 ([@B30]), and are shown in Table [1](#tbl1){ref-type="table"}. Mutants were created using standard yeast manipulation techniques. Yeast cells used in this study were grown at 30°C in either YPD medium or in Synthetic Dextrose (SD) medium supplemented with essential nutrients as required.

###### Strains used in this study

  Reference    Genotype                                                                                                     Strain name
  ------------ ------------------------------------------------------------------------------------------------------------ -------------
  ([@B29])     *lys2:: TySup ade2-1(0c) can1-100 (0c) ura3-52 leu2-3,112 trp1del901 HIS3:: lys2:: ura3- his4::TRP1::his4*   MK166
  This study   MK166 *elg1:HphMX*                                                                                           MK10935
  This study   MK166 ELG1-13Myc:: KanMX                                                                                     MK11534
  This study   MK166 *elg1-TT386/7AA*-13MYC:KanMX                                                                           *MK11880*
  This study   MK166 *elg1-T386/7DD*-13MYC:KanMX                                                                            *MK11881*
  This study   MK166 *elg1-I27A, I93K, II121,122AA*-13MYC:KanMX                                                             *MK11240*
  This study   MK166 *elg1-I27A, I93K, II121,122AA, TT386/7AA*-13MYC:KanMX                                                  MK14904
  This study   MK166 *elg1-I27A, I93K, II121,122AA, TT386/7DD*-13MYC:KanMX                                                  MK14546
  This study   MK166 *elg1-\[289--319\]* deletion and an insertion of GCACG-13MYC:KanMX                                     *MK15340*
  This study   MK166 Rfc5-HA:HphMX                                                                                          MK11293
  This study   MK166 Rfc5-HA:HphMX, ELG1-13Myc::KanMX                                                                       MK13238
  This study   MK166 Rfc5-HA:HphMX, *elg1-TT386/7AA*-13MYC:KanMX                                                            MK13389
  This study   MK166 Rfc5-HA:HphMX, *elg1-TT386/7DD*-13MYC:KanMX                                                            MK13374
  This study   MK166 Rfc5-HA:HphMX, *elg1-I27A, I93K, II121,122AA*-13MYC:KanMX                                              Mk11197
  This study   MK166 Rfc5-HA:HphMX, *elg1-TT386/7AA, I27A, I93K, II121,122AA*-13MYC:KanMX                                   Mk15328
  This study   MK166 Rfc5-HA:HphMX, *elg1-TT386/7DD, I27A, I93K, II121,122AA*-13MYC:KanMX                                   MK15532
  This study   MK166 Rfc5-HA:HphMX, *\[289--319\]* deletion and an insertion of GCACG-13MYC:KanMX                           MK15524
  This study   MK166 *pol30-RR elg1:HphMX*                                                                                  MK11938
  This study   MK166 *pol30-RR* ELG1-13Myc:: KanMX                                                                          MK13396
  This study   MK166 *pol30-RR elg1-TT386/7AA*-13MYC:KanMX                                                                  MK13394
  This study   MK166 *pol30-RR elg1-TT386/7DD*-13MYC:KanMX                                                                  MK13398
  This study   MK166 *pol30-RR elg1-I27A, I93K, II121,122AA*-13MYC:KanMX                                                    MK13661
  This study   MK166 *pol30-RR elg1-I27A, I93K, II121,122AA, TT386/7AA*-13MYC:KanMX                                         MK15402
  This study   MK166 *pol30-RR elg1-I27A, I93K, II121,122AA, TT386/7DD*-13MYC:KanMX                                         MK15740
  This study   MK166 *pol30-RR elg1-\[282--319\]* deletion and an insertion of GCACG-13MYC:KanMX                            MK15438B
  This study   MK166 *rad5:leu elg1:HphMX*                                                                                  MK13081
  This study   MK166 *rad5:LEU2* ELG1-13Myc:: KanMX                                                                         MK13078
  This study   MK166 *rad5:LEU2 elg1-TT386/7AA*-13MYC:KanMX                                                                 MK11218B
  This study   MK166 *rad5:LEU2 elg1-TT386/7DD*-13MYC:KanMX                                                                 MK15863
  This study   MK166 *rad5:LEU2 elg1-I27A, I93K, II121,122AA*-13MYC:KanMX                                                   MK13676
  This study   MK166 *rad5:LEU2 elg1-I27A, I93K, II121,122AA, TT386/7AA*-13MYC:KanMX                                        MK15807
  This study   MK166 *rad5:LEU2 elg1-I27A, I93K, II121,122AA, TT386/7DD*-13MYC:KanMX                                        MK14692
  This study   MK166 *rad5:LEU2 elg1-\[289--319\]* deletion and an insertion of GCACG-13MYC:KanMX                           MK15520
  This study   MK166 *elg1:LEU2, rev3:URA3*                                                                                 MK7212
  This study   MK166 *rev3:URA3*                                                                                            MK7218
  This study   MK166 *elg1:LEU2, rev3:URA3, rad5:URA3*                                                                      MK7383
  This study   MK166 *rev3:URA3 rad5:URA3*                                                                                  MK7392

Site specific mutagenesis {#SEC2-3}
-------------------------

A DNA fragment carrying full length *ELG*1::MYC marked with a *KAN*MX cassette was cloned into pGEM-T Easy Vector (Promega) and subjected to PCR using different forward and reverse primers containing the desired mutations (Table [2](#tbl2){ref-type="table"}). Amplified PCR products were transformed into DH5α cells after digestion with Dpn1 (NEB). Plasmids were isolated and sequenced.

###### List of primers used to generate the Elg1 mutations through site directed mutagenesis

  Oligonucleotide     Sequence (5΄→3΄)   
  ------------------- ------------------ ----------------------------------------------------
  Elg1^I93K^          Forward            ATGACGACGATGATGATCTTAAAGTAATCAGTGATAAGAGTCC
  *elg1-sim1*         Reverse            GGACTCTTATCACTGATTACTTTAAGATCATCATCGTCGTCAT
  Elg1^II121,122AA^   Forward            AGCATGAAGATGATATTTCTGCCGCTTCCACATCGAGAATCAAATC
  *elg1-sim2,3*       Reverse            GATTTGATTCTCGATGTGGAAGCGGCAGAAATATCATCTTCATGCT
  Elg1^TT386,387DD^   Forward            ATATCCTACTAGATTTTACCGACGACCACTATGTCAAAGATTCCTC
  *elg1-386/7DD*      Reverse            GAGGAATCTTTGACATAGTGGTCGTCGGTAAAATCTAGTAGGATAT
  Elg1^TT386,387AA^   Forward            GATATCCTACTAGATTTTACCGCCGCACACTATGTCAAAGATTCC
  *elg1-386/7AA*      Reverse            GGAATCTTTGACATAGTGTGCGGCGGTAAAATCTAGTAGGATATC
  Elg1^linker^        Forward            CTACCTTGAGGAACCGTCTATTGAACAGAATAAATGGTTGTGCATGTGGC
  *elg1-linker*       Reverse            GGAACAAATTCGCTCAAGCTGCTATTTGCTTCGCCGCCACATGCACAACC

To transfer the mutation into the yeast genome, the mutagenized plasmids were digested with NotI (NEB) and transformed into *elg1*::*HphMX* cells. Transformed cells were selected on G418 plates. G418 resistant, hygromycin sensitive colonies were subjected to DNA sequencing to confirm the presence of the particular mutation, and the lack of spurious ones. In the *elg1-linker* allele the sequence of Elg1 between positions 289 and 320 was replaced by a five amino acid linker (Gly-Cys-Ala-Cys-Gly). The *elg1-SIM* mutant harbors the following mutations: I28A, I93K, II121,122AA.

Recombination rate assay {#SEC2-4}
------------------------

Recombination rates were measured as described previously ([@B31]), using the strain MK166 which allows to measure Ty recombination and DRR events.

Protein purification {#SEC2-5}
--------------------

### Elg1--RLC and its mutant forms {#SEC2-5-1}

Elg1--RLC was purified from *Saccharomyces cerevisiae* BJ5464 strain transformed with plasmids pBL448 (encoding *GST-ELG1* under control of *GAL1* promoter) and pBL422 (encoding *RFC2, RFC3, RFC4, RFC5* under control of *GAL1* promoter), which were generously provided by Peter Burgers, according to the protocol of ([@B32]) with minor modifications. Briefly, a fresh overnight culture was diluted 8-fold in fresh synthetic medium lacking tryptophan and uracil, and containing galactose (2%, w/v), glycerol (3%) and lactic acid (3%) and was incubated for 22--24 h at 30°C with shaking. Cells were harvested by centrifugation and stored at −80°C.

Elg1--RLC and its mutants were purified as follows: 70--100 g of yeast paste was lysed by cryo-milling. The resulting powder was dissolved in 200 ml of lysis buffer C, consisting of 50 mM Tris--HCl (pH 7.5), 10% sucrose (w/v), EDTA (10 mM), dithiothreitol (3 mM), nonidet-P40 (0.01%, v/v), NaCl (150 mM) and protease inhibitors (aprotinin, chymostatin, leupeptin, pepstatin A, benzamidine, each at 5 μg/ml). Solid ammonium sulphate was then added to the lysate to a final concentration of 300 mM and the mixture was stirred for 25 min at 4°C. Afterward, 45 μl of 10% Polymin P per 1 ml of the lysate was added, and the mixture was gently stirred at 4°C for 10 min. The crude lysate was clarified by centrifugation (100 000 × g for 90 min). Next, Elg1--RLC complex was precipitated from the cleared lysate using ammonium sulphate (0.35 g/ml), and the precipitate was kept overnight at −80°C. The next day, the precipitate was dissolved in buffer T (25 mM Tris--Cl, 10% (v/v) glycerol, 5 mM EDTA, pH 7.5). The conductivity of the sample was adjusted to be equal of buffer T containing 150 mM NaCl and mixed with 2 ml of glutathione sepharose, equilibrated in the same buffer. After 2--3 h at 4°C, the beads were washed with 150 ml of buffer T, containing 150 mM NaCl. GST-Elg1--RLC was eluted with buffer T, containing 150 mM NaCl, supplemented with 20 mM glutathione (reduced form) and 0.05% ampholytes. Fractions containing the complex were pooled and incubated for 3 h at 4°C with 5--15 μg of PreScission protease. Elg1--RLC complex was then loaded onto 1 ml MonoS column equilibrated with buffer T containing 100 mM NaCl and 0.05% ampholytes. After 10 ml wash with buffer T containing 100 mM NaCl, 0.05% ampholytes, 5 mM MgCl~2~ and 100 μM ATP, the complex was eluted with 20 ml linear gradient of 100--500 mM NaCl. Fractions containing Elg1--RLC were pooled and concentrated in a Vivaspin concentrator and stored in 2 μl aliquots at −80°C.

### PCNA and Polymerase δ purification {#SEC2-5-2}

PCNA and the polymerase δ complex were expressed and purified using the procedure described previously ([@B33]).

### RFC complex purification {#SEC2-5-3}

The RFC complex was purified from *Escherichia coli* using the procedure described by ([@B34]).

D-loop extension assay {#SEC2-6}
----------------------

The D-loop assay was performed essentially as described previously ([@B35]). Briefly, the fluorescent D1 oligonucleotide (90-mer; 3 μM nucleotides) was incubated for 5 min at 37°C with Rad51 (1 μM) in 10 μl buffer R (35 mM Tris--HCl pH 7.4, 2 mM ATP, 2.5 mM MgCl~2~, 50 mM KCl, 1 mM DTT and ATP regenerating system consisting of 20 mM creatine phosphate and 20 μg/ml creatine kinase). Rad54 (150 nM) was added to the reaction in 1 μl, followed by a 3 min incubation at 23°C. The reaction was initiated by addition of the pBluescript replicative form I (50 μM base pairs) in 1.5 μl and incubated for 5 min at 23°C.

The primer extension reaction was assembled as described in Sebesta *et al.* ([@B33]). Briefly, a standard 30 μl reaction mixture containing 12 μl from the D-loop reaction was supplemented with 660 nM RPA, 10 nM PCNA or SUMO-PCNA, 0.3 nM RFC and 33 nM Polδ in buffer O (20 mM Tris--HCl pH 7.5, 5 mM DTT, 0.1 mM EDTA, 150 mM KCl, 40 μg/ml BSA, 8 mM MgCl~2~, 5% glycerol and 75 μM each of dGTP and dCTP). PCNA loading reaction was incubated at 30°C for 5 min. The reaction was stopped by cooling on ice followed by addition of increasing concentrations (10, 50, 250 nM) of Elg1--RLC. Alternatively and where indicated, Srs2 (20 nM) and other indicated proteins (Ulp1, 15 nM) where incorporated. The reaction was continued at 30°C for an additional 5 min. DNA synthesis was initiated by addition of buffer O containing 75 μM dTTP and 0,375 μCi \[α-^32^P\] dATP. After 10 min extension at 30°C, the reactions were stopped, deproteinized and loaded onto a 0.8% (w/v) agarose gel. The gel was either directly analyzed for fluorescent DNA species or dried on DE81 paper and exposed to a Phosphorimager screen and imaged in Fuji FLA 9000 imager with the Multi Gauge software ([@B36]).

ΦX-based extension assay {#SEC2-7}
------------------------

The assay was performed essentially as described in ([@B37]). The reaction (20 μl final volume) was assembled on single primed ФX174 virion ssDNA (5 nM) in buffer O (20 mM Tris--Cl pH 7.5, 5 mM DTT, 0.1 mM EDTA, 70 mM KCl, 0.5 mM ATP, 40 μg/ml BSA, 8 mM MgCl~2~, 5% glycerol and 60 μM each of dGTP and dCTP), in the presence of RPA (1 μM), PCNA (10 nM), RFC (17.5 nM), Pol δ (5 nM) followed by a 5 min incubation at 30°C to allow loading of PCNA on the substrate. DNA synthesis was initiated by adding the start buffer (60 μM dTTP and 0.375 μCi \[α-32P\]dATP in buffer O). After the indicated time at 30°C, the reactions were stopped with SDS (0.5% final) and Proteinase K (0.5 mg/ml) and loaded onto an agarose gel (0.8% (w/v)). After electrophoresis, the gel was dried on DE81 paper, exposed to phosphorimager screen, scanned in Fuji FLA 9000 imager and analyzed with the Multi Gauge software (Fuji).

DNA damage sensitivity {#SEC2-8}
----------------------

Serial 10‐fold dilutions of logarithmic yeast cells were spotted on fresh SD‐complete plates with or without MMS and incubated at 30°C for 3 days.

To calculate relative MMS resistance, all the strains were plated at the same MMS concentration (0.025% for the *POL30 RAD5* background; 0.008% for the *pol30-RR RAD5* background and 0.0012% for the *POL30 rad5*Δ background) such that individual colonies (20--200 per plate) could be obtained and counted after 3 days at 30°C. Three to six individual cultures were tested this way. The Resistance Coefficient of each mutant is the ratio between the average number of colonies in plates with MMS and the average number of colonies obtained in plates without MMS, divided by the results observed in the wt control.

Chromatin fractionation assay {#SEC2-9}
-----------------------------

Cells from 50 ml cultures (OD~600~ \< 1.0) were collected by centrifugation, successively washed with ddH~2~O, PSB (20 mM Tris--Cl pH 7.4, 2 mM EDTA, 100 mM NaCl, 10 mM b-ME) and SB (1 M Sorbitol, 20 mM Tris--Cl pH 7.4), and transferred to a 2 ml ependorff tube. Cells were suspended in 1 ml SB, 30 μl Zymolase 20T (20 mg/ml in SB) was added, and samples were incubated at 30°C with rotation until \>85% spheroplasts were observed (60--90 min). Spheroplasts were collected by centrifugation (2K, 5 min, 4°C), washed twice with SB, and suspended in 500 ml EBX (20 mM Tris--Cl pH 7.4, 100 mM NaCl, 0.25% Triton X-100, 15 mM β-ME + protease/phosphatase inhibitors). Triton X-100 was added to a 0.5% final concentration to lyse the outer cell membrane, and the samples kept on ice for 10 min with gentle mixing. An aliquot was taken for western blot analysis (WCE), and the remainder of the lysate was layered over 1 ml NIB (20 mM Tris--Cl pH 7.4, 100 mM NaCl, 1.2 M sucrose, 15 mM β-ME + protease/phosphatase inhibitors) and centrifuged at 12K RPM for 15 min, at 4°C. A sample of the upper cytoplasmic layer fraction was taken for Western blot analysis (cytoplasm) and the rest of the supernatant was discarded. The glassy white nuclear pellet was suspended in 500 μl EBX and Triton X-100 was added to a 1% final concentration to lyse the nuclear membrane. The chromatin and nuclear debris were collected by centrifugation (15K, 10 min, 4°C). Chromatin was suspended in 50 μl Tris pH 8.0 for western blot analysis (Chromatin). To each fraction an equal volume of 2× SDS-PAGE loading buffer (60 mM Tris pH 6.8, 2% SDS, 10% glycerol, 0.2% bromophenol blue, 200 mM DTT) was added, samples were incubated at 95°C for 5 min and sonicated at 80%, 5 cycles, 10 s per cycle. Samples were analyzed by SDS-PAGE and western blot analyses.

Western blotting {#SEC2-10}
----------------

Western blotting and quantification were performed as described previously. Antibodies used for Western blotting were mouse monoclonal anti-PCNA diluted 1:1000 in 5% skim milk (ab70472, Abcam), rabbit polyclonal anti-histone H3 diluted 1:5000 in 5% skim milk (ab46765, Abcam), rabbit polyclonal anti RPS6 diluted 1:1000 in 5% BSA (ab40820, Abcam), mouse monoclonal anti MYC diluted 1:1000 in 5% skim milk (sc-40 Santa Cruz) Monoclonal Mouse anti-actin diluted 1:5000 in 5% skim milk (ab3280, Abcam). The western results were quantified using ImageJ software; at least three blots were used for each calculation.

RESULTS {#SEC3}
=======

Homology modeling of Elg1 to identify novel mutation sites {#SEC3-1}
----------------------------------------------------------

In order to investigate the relationship between Elg1--RLC mediated PCNA unloading and genomic instability, we first generated a predicted structural model of the yeast Elg1 protein. All subunits of the RFC clamp loader complex (Rfc1--5) contain an AAA+ ATPase domain, that is required for PCNA loading \[reviewed in ([@B38])\]. Elg1\'s AAA+ ATPase domain is believed to be inactive ([@B39]), but it bears a sequence and structure similarity to the Rfc1 AAA+ domain. Taking advantage of the previously published crystal structure of the RFC complex together with PCNA ([@B10],[@B40]), we were able to construct a homology model of Elg1\'s central AAA+ domain structure and its complex with PCNA (Figure [1A](#F1){ref-type="fig"}--[C](#F1){ref-type="fig"}). Based on this structural model we marked several regions for mutagenesis (Figure [1C](#F1){ref-type="fig"}): Threonines 386/7 in Elg1 correspond to asparagines 694 and 695 of the human Rfc1, which were shown to be involved in the interaction between Rfc1 and the C-terminal region of PCNA ([@B40]). These two threonine residues were mutated to differently charged amino acids: either aspartic acid (hereby referred to as *elg1-386/7DD* mutant) or to alanines (*elg1-386/7AA* mutant). By introducing these mutations we expected to reduce the strength of interaction between Elg1 and PCNA and therefore to disturb Elg1\'s clamp unloading activity.An unstructured loop, spanning from aa 290 to aa 319, containing a hydrophobic patch. This loop is conserved throughout all Elg1 orthologs but is absent in other components of the RFC complex and in the other Rfc1-like proteins (Ctf18 and Rad24). An unstructured loop with a hydrophobic patch is a possible protein- protein interaction site and therefore we deleted this region to identify functions unique to the Elg1--RLC, replacing it with a short flexible linker (see Materials and Methods). We hereafter refer to this allele as *elg1-linker*.Putative SUMO interaction motifs (SIMs) within the N-terminal domain of Elg1 were shown to affect the interaction between Elg1 and SUMOylated PCNA ([@B19]). Mutations in these motifs are likely to disrupt the interaction of Elg1 with the SUMO moiety, but not other interactions ([@B19]). The point mutations are located at the following positions: SIM1: I28A, SIM2: I93K, SIM3: II121,122AA.Finally, we combined the *elg1-sim* and *TT386/387* alleles; these alleles are referred to as *elg1-sim+386/7AA* and *elg1-sim+386/7DD*. In these alleles, we expect the interactions with both PCNA and SUMO to be disrupted.

![Homology modeling of the Elg1 central region. (**A**) A side view of the RFC complex subunits (colored from blue to green) with PCNA (pink). A model of the Elg1 AAA+ region (yellow) is predicted according to the homology with Rfc1 (blue). (**B**) A prediction of the interaction site between Elg1 AAA+ region and PCNA. Lysines 127 and 164 of PCNA are indicated. The *elg1-sim* mutations, located at Elg1\'s N-terminus, is not displayed here. (**C**) A schematic representation of the Elg1 protein and the generated point mutations.](gkw1348fig1){#F1}

Corresponding isogenic strains carrying MYC tagged versions of wt or mutant *elg1* alleles were generated, at the normal genomic loci and under regulation of the endogenous promoter. The Elg1 protein level remains unchanged in different *elg1* alleles compared to the wt ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}). Next, we performed co-IP and showed that the interaction between the various Elg1 alleles and the RFC small subunits is also not altered in the mutants ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}). Hence, any phenotypic change caused by these mutations is not a consequence of reduced protein expression or a reduced formation of the Elg1--RLC complex. This conclusion is further supported by the fact that all mutations presented here are recessive and the MMS sensitivity of these strains can be fully complemented by a centromeric plasmid carrying the wt *ELG1* allele ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}).

Elg1 mutants accumulate varying levels of PCNA on the chromatin {#SEC3-2}
---------------------------------------------------------------

Cumulative results from several laboratories suggest that the main role of the Elg1--RLC is to unload PCNA and indeed, *elg1Δ* cells accumulate PCNA on chromatin ([@B18]--[@B20],[@B23]). As PCNA can be post-translationally modified, various types of PCNA modifications can be distinguished according to their electrophoretic mobility \[([@B18],[@B19],[@B41],[@B42]), [Supplementary Figure S1D](#sup1){ref-type="supplementary-material"}\]. In *elg1Δ*, the increased accumulation of SUMOylated PCNA is the most dramatic (∼50-fold increase, compared to only 3-fold increase in accumulation of unmodified PCNA (Figure [2](#F2){ref-type="fig"}). Fractionation experiments revealed large differences in the ability of the various *elg1* mutants to unload PCNA from chromatin: The *elg1-386/7AA* mutant accumulates only a small amount of PCNA on the chromatin, suggesting that this mutant retains most of Elg1\'s unloading ability. In contrast, the *elg1-386/7DD* mutant accumulates a larger proportion of both SUMOylated and unmodified PCNA on the chromatin. When the three SIM motifs in the N-terminal domain of Elg1 are mutated (*elg1-sim*), a very mild accumulation of both modified and unmodified PCNA is observed on the chromatin (Figure [2](#F2){ref-type="fig"}). The double mutant *elg1-sim + 386/7DD* is as defective in PCNA unloading as the *elg1-*386/7DD allele, which shows that the SIM motifs are not only mediating the interaction of Elg1 with the SUMO moiety attached to PCNA, but are also important for the interaction with PCNA itself, either directly (by changing the affinity of Elg1 to PCNA) or indirectly (by interacting with another SUMOylated protein to stabilize the interaction and promote the unloading process). In contrast to these results, the *elg1-linker* mutant appears completely proficient in PCNA unloading, and did not accumulate any form of PCNA on the chromatin (Figure [2](#F2){ref-type="fig"}).

![*elg1* mutants exhibit variability in PCNA unloading. A fractionation assay followed by western blot to detect PCNA levels shows different modified (**A** and **B**) and unmodified (**C** and **D**) PCNA levels on the chromatin in the various *elg1* mutants in MK166 strain background. Histone H3 and RPS6 served as chromatin-bound and unbound controls. Histone H3 levels were also used as a loading control. At least 3 experiments were used for quantitation and the error bars represent the standard error of the mean.](gkw1348fig2){#F2}

After determining the PCNA unloading activity of each of the point mutants, we investigated whether it correlates with the severity of the mutants' phenotypes.

Point mutations in Elg1 impinge on its ability to inhibit *in vitro* DNA synthesis {#SEC3-3}
----------------------------------------------------------------------------------

Since Elg1--RLC preferentially unloads SUMOylated PCNA from the chromatin during DNA replication ([@B18],[@B21]), we asked whether a similar biochemical activity is also necessary for DNA repair. Furthermore, we wished to study the activity of Elg1 *in vitro* using a purified complex. We therefore modified an already existing *in vitro* repair/replication system \[Figure [3A](#F3){ref-type="fig"}; ([@B33],[@B43])\]. In our assay, Pol δ synthesizes DNA using a D-loop as primer, successfully recapitulating the DNA synthesis step required in all homology-dependent repair/tolerance pathways ([@B44],[@B45]) (Figure [3A](#F3){ref-type="fig"}, upper panel). Importantly, we have successfully used this assay to determine that the Srs2 helicase dissociates the complex between SUMO--PCNA and Polymerase (Pol) δ, thereby regulating the length of extension products during PCNA-dependent DNA repair synthesis ([@B33]). The known mechanism of action of Srs2 in the assay served as a unique control for our experiments with Elg1--RLC. In this assay, addition of Elg1--RLC together with SUMO--PCNA resulted in a reproducible 5-fold reduction in DNA synthesis (Figure [3A](#F3){ref-type="fig"}, compare lanes 9 and 12), which did not occur upon addition of unmodified PCNA to the reaction (Figure [3A](#F3){ref-type="fig"}, compare lanes 5 and 8), suggesting that Elg1--RLC unloads SUMO--PCNA *in vitro*. To further corroborate the role of SUMO, we tested whether the presence of Ulp1, a SUMO-specific protease that deSUMOylates proteins, together with Elg1--RLC, would reverse the observed inhibition. As shown in [Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}, addition of Ulp1 resulted in restoration of DNA synthesis, suggesting that Elg1--RLC indeed acted preferentially upon SUMOylated PCNA.

![Elg1 mutants affect DNA synthesis *in vitro*. (**A**) Upper panel. Schematic representation of the reaction. (see Materials and Methods). Lower panel. Elg1--RLC inhibits DNA synthesis *in vitro*, preferentially in the presence of SUMOylated PCNA. (**B**) *elg1-386/7AA* mutant complex inhibits DNA synthesis in the presence of SUMOylated PCNA, whereas *elg1-386/7DD* complex is defective in the inhibition. (**C**) *elg1-sim* is proficient in inhibiting DNA synthesis in the presence of unmodified PCNA. (**D**) *elg1-sim* is only partially proficient in inhibiting DNA synthesis in the presence of SUMO--PCNA.](gkw1348fig3){#F3}

Elg1--RLC also efficiently inhibited DNA synthesis in the well-defined ΦX-174 system ([@B37]) in the presence of SUMO-PCNA ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}), suggesting that the Elg1--RLC PCNA unloading activity is independent of the substrate tested, and therefore relevant for both DNA repair and DNA replication.

Srs2 inhibits DNA synthesis by dissociating the DNA polymerase from the reaction ([@B33]). To test the mode of action of Elg1, we carried out order-of-addition experiments ([Supplementary Figure S2C and D](#sup1){ref-type="supplementary-material"}). Both Srs2 and the Elg1--RLC complex inhibit DNA synthesis *in vitro* ([Supplementary Figure S2C](#sup1){ref-type="supplementary-material"}, lane 9 and [Supplementary Figure S2D](#sup1){ref-type="supplementary-material"}, lane 9). When SUMO--PCNA remains on the DNA, an addition of the de-SUMOylating enzyme Ulp1 after the action of Srs2 restarts DNA synthesis ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}, lane 13), as Srs2 has 7-fold lower affinity to PCNA over SUMO--PCNA ([@B46]). In contrast, when an analogous experiment was performed with Elg1--RLC, we observed no restart of DNA synthesis when Ulp1 was added alone ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}, lane 13). Only when increasing concentrations of the RFC complex were added along with Ulp1, did we observe restart of DNA synthesis. These results are in line with the model in which Elg1--RLC unloads SUMO--PCNA from DNA and thus more RFC complex is needed in order to reload it and allow further DNA synthesis *in vitro*.

Interestingly, at high Elg1--RLC concentrations a small decrease in mobility of the band that represents the reaction product (e.g.: Figure [3A](#F3){ref-type="fig"}, lane 8) can be observed. This observation points to the possibility that Elg1--RLC may interact with the free PCNA in the reaction, reducing the amount of free PCNA that is able to compete for Polymerase δ binding, and resulting in longer DNA synthesis tracks.

Next, we compared the mutants known to accumulate PCNA on chromatin in this *in vitro* assay. While *elg1-386/7AA* mutant alleles showed a minor inhibition of *in vitro* DNA synthesis, the addition of the *elg1-386/7DD* protein did not inhibit DNA synthesis (Figure [3B](#F3){ref-type="fig"}), suggesting that this mutant is unable to unload SUMO-PCNA. These results correlate with the PCNA accumulation data and show that the different *elg1* mutants inhibit DNA synthesis *in vitro* in accordance with their PCNA unloading capabilities *in vivo*.

The *elg1-sim* mutant had the same inhibitory effect on DNA synthesis in the presence of unmodified PCNA as the wt Elg1 (Figure [3C](#F3){ref-type="fig"}, lanes 7 and 10), but when SUMO--PCNA was added to the reaction, the inhibition by *elg1-sim* was not as high as by wt Elg1 (Figure [3D](#F3){ref-type="fig"}, lanes 7 and 10). This is in accordance with the role of the SIM motives as mediators of the interaction of Elg1 with the SUMO moiety attached to PCNA.

The sensitivity of *elg1* mutants to DNA damage correlates with their PCNA accumulation status {#SEC3-4}
----------------------------------------------------------------------------------------------

In order to determine the significance of PCNA accumulation in genomic stability, we tested the sensitivity of various *elg1* mutants to DNA damage. MMS (Methyl Methanesulfonate) is a DNA damaging agent that causes DNA methylation. When compared to the *elg1* Δ allele, the *elg1-386/7AA, elg1-sim* and *elg1-linker* mutants are resistant to MMS whereas the *elg1-386/7DD* mutant exhibits an intermediate sensitivity to MMS. The double *elg1-sim+386/7DD* mutant is as sensitive to DNA damage as the *elg1*Δ strain, showing an additive effect for the SIM motifs and the PCNA interaction site mutations regarding DNA damage sensitivity (Figure [4A](#F4){ref-type="fig"}). In order to better quantify the effect of the various mutations on the sensitivity to DNA damaging agents, we devised a Resistance Coefficient (RC) parameter (see Materials and Methods for details). In brief, all mutants and the wt strain were diluted and plated on plates without or with 0.025% MMS, and the survival on MMS was calculated for each strain, normalized by comparing it to the survival of the wt. When the RC value is plotted against the relative PCNA accumulation value (derived from the fractionation assays followed by a western blot), a clear correlation can be observed. Figure [4C](#F4){ref-type="fig"} and [D](#F4){ref-type="fig"} show that the MMS resistance of the *elg1* mutants is tightly correlated with both the SUMOylated and unmodified PCNA accumulation status of these mutants (*R*^2^ = 0.81^,^ and 0.90, respectively). Very similar results were obtained with 4-nitroquinoline 1-oxide (4-NQO), a DNA damaging agent that forms bulky adducts ([@B47]) (Figure [4B](#F4){ref-type="fig"}). Taken together, these results support a model in which the DNA damage sensitivity of *elg1Δ* cells is caused by PCNA accumulation on the chromatin.

![DNA damage sensitivity of *elg1* mutants correlate with PCNA accumulation. (**A** and **C**) Serial dilutions of yeast cultures on minimal SD-complete plates with or without methylmethane sulphonate (MMS) or 4-nitroquinoline 1-oxide (4-NQO) in the indicated concentration show different sensitivities of *elg1* mutants in MK166 strain. (**B** and **D**) The MMS resistance coefficient calculated from a plating assay plotted against unmodified and SUMOylated PCNA accumulation, respectively.](gkw1348fig4){#F4}

The high recombination rates of *ELG1* mutants are dependent on the PCNA unloading activity {#SEC3-5}
-------------------------------------------------------------------------------------------

It has been reported that *elg1Δ* cells exhibit high rates of homologous recombination \[HR; ([@B19],[@B31])\]. Using MK166, a strain in which different types of recombination events can be monitored, we measured the rate of direct repeat recombination (DRR) and non-reciprocal recombination between Ty elements (gene conversion) ([@B30]) (see Materials and Methods and Figure [5A](#F5){ref-type="fig"}). As previously described ([@B31]), *elg1Δ* strains exhibit a greatly increased rate of HR (∼5-fold increased for DRR, ∼18-fold for Ty recombination). The DRR and Ty recombination rates of the *elg1-386/7AA* and *elg1-sim* mutants are comparable to those of the wt strain, whereas in the *elg1-386/7DD* mutant the Ty recombination rate is intermediate and the DRR rate is similar to that of *elg1Δ*. Combining the SIM mutations with the *386/7* replacements results again in an additive effect, as in the DNA damage sensitivity assay, and the rates of Ty recombination and DRR of the double mutant *elg1-sim+386/7DD* are close to those seen in the strain harboring a complete *ELG1* deletion. The *elg1-linker* mutation did not affect the levels of homologous recombination (Figure [5B](#F5){ref-type="fig"}). Thus, we could see a strong correlation between the rates of recombination and the level of unmodified or SUMOylated PCNA accumulation (*R*^2^ = 0.80 and 0.88, respectively; Figure [5C](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"}). Our results show that the *elg1* mutants that accumulate more PCNA on the chromatin are more sensitive to DNA damage and have higher recombination rates and thus PCNA accumulation correlates with genomic instability.

![Recombination rates of *elg1* mutants are correlated with PCNA accumulation. (**A**) A schematic representation of the MK166 recombination levels monitoring system. (**B**) Recombination rates were calculated for various *elg1* mutants by plating the MK166 yeast strain on selective media (see Materials and Methods). (**C** and **D**) The recombination rates plotted against unmodified and SUMOylated PCNA accumulation, respectively.](gkw1348fig5){#F5}

The MMS sensitivity of *elg1Δ* is related to unmodified PCNA unloading {#SEC3-6}
----------------------------------------------------------------------

PCNA can undergo ubiquitination at lysine 164, and SUMOylation at lysines 127 and 164 ([@B3]). *pol30-KK164,127RR* (hereafter referred to as *pol30-RR*) is a mutant allele of PCNA in which these two critical lysines are mutated to an arginine, preventing post translational modifications.

We tested various mutant *elg1* alleles in the background of the *pol30-RR* mutation in order to determine the importance of PCNA modifications for the activity of the Elg1--RLC (Figure [6](#F6){ref-type="fig"}). Significantly, the *elg1Δ* mutation increases the sensitivity to MMS of a *pol30-RR* mutant, implying that part of the *elg1Δ* phenotype is independent of PCNA modifications (Figure [6A](#F6){ref-type="fig"}).

![The sensitivity to MMS in the various mutants is not dependent on PCNA modifications. (**A**) Serial dilutions of yeast cultures on minimal SD-complete plates with or without MMS in the indicated concentrations show different sensitivities of *elg1* mutants to MMS in MK166 *pol30-RR* background. (**B**) PCNA levels on the chromatin of the same strains. (**C**) The RC in a *pol30-RR* background correlates with the ability of the different *elg1* mutants to unload PCNA.](gkw1348fig6){#F6}

The MMS sensitivity of the mutants in a *pol30-RR* background shows the same gradient of sensitivities as in the *POL30* background (Figure [4A](#F4){ref-type="fig"}), with a general shift towards more severe sensitivity: the *elg1-386/7DD* mutant is as sensitive as *elg1Δ, elg1-386/7AA* is less severe than *elg1-386/7DD* but more sensitive than the wt. The *elg1-sim* and *elg1-linker* mutations show no MMS sensitivity, and combining the 386/7 mutations with the SIM mutations resulted in an additive phenotype: the *pol30-RR elg1-sim+386/7AA* mutant shows a more severe phenotype than the single mutants and the *pol30-RR elg1-sim+386/7DD* combination shows a sensitivity as high as that of the *pol30-RR elg1Δ* double mutant. The unmodified PCNA accumulation level in the different *elg1* mutant strains varies in the *pol30-RR* background according to the same gradient that was observed in the wt background: *elg1-386/7DD* and *elg1-sim+386/7DD* mutants accumulate unmodified PCNA at levels similar to those seen in the *elg1Δ pol30-RR* double mutant. *elg1-386/7AA, elg1-sim* and *elg1-sim+386/7AA* accumulate only a small amount of unmodified PCNA and the *elg1-linker* mutants do not accumulate unmodified PCNA at all. Thus, the correlation between DNA damage sensitivity and PCNA accumulation is not affected by mutations that preclude PCNA modification (*R*^2^ = 0.847; Figure [6C](#F6){ref-type="fig"}).

Taken together, our results show that the phenotypic variation observed among the *elg1* mutants correlates with the amount of PCNA that is retained on the chromatin, irrespectively of its modification status.

Suppression of the DNA damage sensitivity of *rad5Δ* mutants {#SEC3-7}
------------------------------------------------------------

Another interesting phenotype of *elg1Δ* is its suppression of the sensitivity to MMS of the *rad5Δ* mutant ([@B19]). *RAD5* is best known as an E3 ubiquitin ligase that poly-ubiquitinates PCNA in response to DNA damage, together with the E2 Mms2/Ubc13 ([@B48],[@B49]). Poly-ubiquitination of PCNA occurs sequentially after mono ubiquitination by the SUMO-dependent Ubiquitin ligase Rad18 ([@B50]) and is required to direct the cell towards an error-free lesion bypass pathway. In addition, Rad5 has an helicase activity that has been suggested to reverse fork progression ([@B51]). *rad5*Δ cells are very sensitive to MMS and a deletion of *ELG1* partially suppresses this high sensitivity. *ELG1* deletion was shown to specifically suppress the MMS sensitivity caused by defects in the E3 ubiquitin ligase activity of Rad5 ([@B19]). The mechanism by which a deletion of *ELG1* suppresses *rad5Δ* MMS sensitivity and the PCNA modification status that is required to allow this suppression effect is unclear. We decided to approach this question by trying to correlate the PCNA unloading activity and the ability of the different *ELG1* mutations to suppress the MMS sensitivity of *rad5Δ*. With the exception of the *elg1-linker* allele, which seems to retain the full activity of wt Elg1, all the other mutations suppress *rad5Δ* MMS sensitivity to the same extent as the *elg1*Δ allele (Figure [6A](#F6){ref-type="fig"}). Strains deleted for *RAD5* accumulate suppressors at a very high rate and therefore it was challenging to perform fractionation assays; Figure [6B](#F6){ref-type="fig"} shows that the accumulation of unmodified PCNA of *elg1* mutants in the absence of *RAD5* was similar to that seen in the *RAD5* background, with the *elg1-386/7DD* and *elg1-sim+386/7DD* mutants showing the highest levels. Interestingly, the SUMOylated fraction of PCNA, which is usually much less prominent than the unmodified fraction, was not consistently detected in *rad5Δ* mutants regardless of the *ELG1* allele in the strain (see Discussion). The RC scores for unmodified PCNA accumulation levels in the various mutants in the presence of MMS in the *rad5*Δ background showed no correlation (R^2^ = 0.052) with MMS sensitivity (Figure [6C](#F6){ref-type="fig"}). The almost-universal suppression of *rad5*Δ by *elg1* alleles can be interpreted in two ways (see model in Figure [8C](#F8){ref-type="fig"}): (i) Reduced Elg1--RLC activity leads to both modified and unmodified PCNA accumulation. In the absence of the error free DNA repair pathway the SUMOylated PCNA that is retained on the chromatin recruits the Srs2 helicase ([@B8]) and thus causes an inhibition of the HR pathway. However, the unmodified or the mono-ubiquitinated PCNA that is retained on the chromatin is enough to enable a pathway that can partially bypass the DNA damage sensitivity, and this is achieved in all the mutants tested, with the exception of the *elg1-linker* allele, which seems to retain the full capacity of PCNA unloading of wt Elg1 (Figure [6B](#F6){ref-type="fig"} and [C](#F6){ref-type="fig"}). (ii) Alternatively, the suppression of the MMS sensitivity phenotype of *rad5*Δ mutants is a consequence of another activity of Elg1 that is not related to PCNA unloading, and which is abolished by all the mutations except for the *elg1-linker* mutant. We prefer the first option, which is more parsimonious. In addition, we have recently found that mutations which prevent Elg1 phosphorylation upon DNA damage (S6,8,112A and S,6,8,112E) suppress the MMS sensitivity of *rad5*Δ, even when, in a *RAD5* genetic background, they show no MMS sensitivity ([@B52]). The large number of independent mutants with partial or total reduction of Elg1 PCNA unloading activity that are able to suppress the DNA damage sensitivity of *rad5*Δ mutants suggests that an accumulation of a low level of PCNA that is not SUMOylated is sufficient to alleviate this suppression phenotype.

Suppression of the MMS sensitivity of *rad5Δ* mutants requires PCNA modification {#SEC3-8}
--------------------------------------------------------------------------------

To further understand the mechanism that suppresses the sensitivity of *rad5Δ* mutants when *ELG1* is deleted, we introduced all the *elg1* mutations into a *rad5Δ pol30-RR* background, in which PCNA cannot be modified, and tested the ability of the various strains to grow in the presence of MMS. The *pol30-RR* allele suppresses the *rad5Δ* MMS sensitivity (to the level of resistance observed in the single *pol30-RR*) showing that the MMS sensitivity of *rad5Δ* is due to PCNA modification. Importantly, deletion of *ELG1* had the same additive effect with the *pol30-RR* allele in the double mutant *pol30-RR rad5*Δ background and in the single *pol30-RR* background, and so did the various *elg1* alleles (compare Figures [6A](#F6){ref-type="fig"} and [8A](#F8){ref-type="fig"}). This implies that while PCNA modifications are a pre-requisite for *rad5Δ* MMS sensitivity (there is no sensitivity if PCNA is not modified), the level of PCNA unloading by Elg1--RLC has a different phenotypic effect that depends on the PCNA modification status (in a modifiable PCNA background all *elg1* alleles have the same effect, whereas a gradient of phenotypes is seen when PCNA is unmodified).

To directly test the effect of PCNA accumulation on the chromatin and the PCNA modifications required to allow *elg1Δ* suppression of *rad5Δ* MMS sensitivity, we overexpressed three PCNA alleles: modifiable wt *POL30*, the unmodifiable *pol30-RR* allele, or a PCNA allele that cannot be ubiquitinated (*pol30-164R*), in wt, *elg1Δ, rad5Δ* and *rad5Δ elg1Δ* mutant strains (Figure [8B](#F8){ref-type="fig"}). It has been shown ([@B22],[@B53]), that PCNA overexpression causes an accumulation of PCNA on the chromatin. Overexpression of *pol30-RR* confers slight MMS sensitivity to both wt and *elg1Δ* strains. However, whereas overexpression of *POL30* has no effect on the wt strain, it leads to increased sensitivity in the *elg1Δ* strain; this is consistent with the accumulation of PCNA being responsible for the MMS sensitivity: when Elg1--RLC is active, some of the PCNA can be removed from the chromatin; when it is inactive (in *elg1Δ* strains), PCNA accumulates even more. Interestingly, the slight sensitivity conferred by the overexpression of *pol30-RR* is similar whether Elg1 is present or absent, showing again a preference of the Elg1--RLC for unloading SUMOylated PCNA ([@B19]).

Consistent with the idea that PCNA modifications are required for *elg1*Δ suppression of the MMS sensitivity of *rad5Δ*, overexpression of neither *pol30-RR* nor *pol30-164R* suppresses the sensitivity of a *rad5Δ* mutant. Only the overexpression of modifiable *POL30* is able to suppress the MMS sensitivity of *rad5Δ* (Figure [8B](#F8){ref-type="fig"}). These results suggest that lysine 164, the target of mono-ubiquitination, is essential for the suppression of *rad5Δ*. The suppression effect of *pol30-164R* overexpression is epistatic to the effect caused by deletion of *ELG1*, again supporting the idea that the suppression of *rad5Δ* by deletion of Elg1 is due to the accumulation of mono- ubiquitinated PCNA. Accordingly, overexpression of PCNA that cannot be ubiquitinated (either *pol30-164R* or *pol30-RR*) abolishes the suppression effect conferred by *elg1Δ* in the *rad5Δ* background (Figure [8B](#F8){ref-type="fig"}). In contrast to the almost full suppression observed in *rad5Δ siz1Δ* or *rad5Δ srs2Δ* double mutants ([@B8],[@B17],[@B54]), which are explained by the availability of HR as an alternative repair mechanism in the absence of the error-free Rad5-initiated bypass pathway, deletion of *ELG1* has a milder effect, which can be explained by the use of the less efficient trans-lesion synthesis (error-prone) pathway upon accumulation of low levels of mono-ubiquitinated PCNA. Mono-ubiquitination of PCNA enables the recruitment of trans-lesion synthesis polymerases, such as Rev3 (PolZeta) \[reviewed in ([@B3])\].

In order to test that hypothesis we deleted *REV3* in the *rad5Δ elg1Δ* background. As expected, ablation of the trans-lesion synthesis polymerase abolished the suppression effect of *elg1Δ* on *rad5Δ* (Figure [8C](#F8){ref-type="fig"}). We therefore conclude that the suppressive effect of *elg1* mutations in the *rad5Δ* background is caused by accumulation of mono-ubiquitinated PCNA on the chromatin, which partially rescues *rad5Δ* hyper sensitivity phenotype in a *REV3*- dependent manner.

DISCUSSION {#SEC4}
==========

In this paper, we have investigated the correlation between the Elg1\'s clamp unloading activity, the accumulation of modified and unmodified PCNA on the chromatin, and genomic instability. In order to do so we generated a set of mutations in designated regions with a differential ability to unload PCNA from the chromatin.

By predicting the structure of Elg1\'s central domain we identified threonines 386 and 387 as residues that might mediate the interaction between PCNA and Elg1. The strains that contain mutations in these residues exhibit a retention of PCNA on the chromatin. It was previously reported that Elg1 contains a distorted PIP motif in the N terminal domain. This motif, however, showed no effect on DNA damage sensitivity nor on the actual interaction with PCNA ([@B39]). It was recently shown ([@B55]) that the PIP motives of various proteins mediate the interaction of the protein with partners other than PCNA, and we suspect that this could be the case in the Elg1 putative PIP motif.

We have also mutated a unique unstructured loop containing a hydrophobic patch that is conserved among *ELG1* orthologs but not in other Rfc1-like proteins. Surprisingly, deletion of this loop had no noticeable phenotype and the mutants were able to carry out all the known activities of Elg1 at wt levels. The function of this loop thus remains unknown.

All previous *in vitro* work with Elg1 was carried out with Elg1--RLC immunoprecipitated from yeast cells. Here we show for the first time, using purified proteins, that the Elg1 complex inhibits DNA synthesis, by a mechanism that is different from that shown for the Srs2 helicase ([@B33]): Whereas Srs2 interacts with SUMOylated PCNA and dissociates it from the DNA polymerase, the Elg1--RLC unloads the modified PCNA altogether (Figure [3](#F3){ref-type="fig"} and [Supplementary Figure S2C and D](#sup1){ref-type="supplementary-material"}).

We have tested the PCNA accumulation status of the mutants and discovered a gradient of accumulation levels, which reflects the capacity of the various mutants to unload PCNA from chromatin (Figure [2](#F2){ref-type="fig"}). A striking correlation was found between the PCNA unloading ability and genomic instability phenotypes such as: MMS sensitivity, 4-NQO sensitivity and the recombination frequency of the *elg1* mutant strains. This correlation suggests that the sensitivity to DNA damage and the increased recombination rate in *elg1* mutants are the consequence of the retention of PCNA on the chromatin, probably through the inappropriate recruitment of interacting partners that are important for choosing the repair mechanism or the processing of recombination intermediates.

*ELG1* is not an essential gene; in its absence PCNA is eventually unloaded by alternative mechanisms and therefore either the physical accumulation of the clamps for an extended period of time or the delay in completing DNA replication cause genome instability.

What form of PCNA (modified or unmodified) is responsible for the phenotypes of *elg1* mutants? Abolishing PCNA modifications (by using *pol30-RR* allele) caused a sensitization of all the *elg1* mutants in a way that retained these mutant\'s graduated differential DNA damage sensitivity phenotype observed in the *POL30* background (Figure [4](#F4){ref-type="fig"}). Thus, PCNA modification is not a pre-requisite for the enhanced MMS sensitivity of *elg1* mutants. While this paper was in review, Johnson and co-workers presented additional evidence that the MMS sensitivity of *elg1Δ* is a consequence of PCNA retention on the chromatin ([@B22]). Taken together, our results fit a model in which PCNA SUMOylation functions as a hallmark of PCNA retention and its levels build up when PCNA is not unloaded from the chromatin by the Elg1 complex. Since PCNA requires proximity or attachment to DNA in order to get SUMOylated ([@B42]), it is possible that the accumulation of SUMOylated PCNA on the chromatin is time-dependent, and thus more SUMOylated proteins are seen on the chromatin as a function inversely proportional to the activity of the various *elg1* mutants.

Paradoxically, we see that the suppressive effect of *elg1* mutations on *rad5Δ* requires PCNA modification. Except for the *elg1-linker* mutants, all the other mutants were able to suppress the MMS sensitivity conferred by deletion of *RAD5*. Previously, several groups have shown that the sensitivity of *rad5Δ* mutants to genotoxic agents can be suppressed either by preventing PCNA SUMOylation (by using the *pol30-RR* allele or deleting *SIZ1*), or by deleting the helicase *SRS2* ([@B8],[@B17],[@B54]). The current model thus proposes that the MMS sensitivity of *rad5Δ* strains is caused by PCNA SUMOylation that indirectly prevents the cells from repairing DNA damage by HR. The suppression of *rad5Δ* by mutations in *ELG1* is milder than that seen in the absence of PCNA SUMOylation or Srs2, and it was unclear what is the precise mechanism by which it takes place. As most *elg1* mutants tested in this study, and in a recently published one ([@B52]) show full suppression, irrespectively of the position of the mutation or of the severity of the unloading defect, it appears that a minor accumulation of PCNA provides a threshold above which the suppression can occur. Since the only allele that failed to suppress the sensitivity of a *rad5Δ* strain is the *elg1-linker* allele, which displays wild type levels of PCNA unloading activity, the suppression effect seems related to the clamp unloading activity of Elg1. Overexpression experiments (Figure [8B](#F8){ref-type="fig"}) showed that the suppression requires modifiable, and specifically mono-ubiquitinated, PCNA. which would allow lesion bypass by recruiting a trans-lesion synthesis polymerase ([@B56]). Indeed, deletion of *REV3*, the gene encoding the main trans-lesion synthesis polymerase in yeast, abolished the suppression conferred by deletion of *ELG1* (Figure [8C](#F8){ref-type="fig"}). Previous genetic results indeed showed that *rad5Δ* mutants exhibit high levels of mutagenesis, which depend both on the TLS polymerase encoded by *REV3* and on the mono-ubiquitination activity of the *RAD18* gene ([@B57]). Interestingly, whereas a single copy of the *pol30-RR* allele in the genome suppresses the sensitivity of *rad5Δ* mutants (compare Figures [7A](#F7){ref-type="fig"} and [8A](#F8){ref-type="fig"}) and similar results are observed when wt *POL30* is overexpressed (Figure [8B](#F8){ref-type="fig"}), overexpression of *pol30-RR* and of *pol30-164R* (in the presence of a wt genomic PCNA copy) failed to show such effect, even in the absence of Elg1--RLC activity. These results imply that the sensitivity of *rad5Δ* to MMS is due to the presence of SUMOylated PCNA; if the only copy of PCNA present cannot be modified, a reduced sensitivity to genotoxins is seen. This is consistent with our model (Figure [8D](#F8){ref-type="fig"}): In wt cells, lesions are repaired in an error-free manner by the *RAD5* pathway, enabled by poly-ubiquitination of PCNA. In the absence of the Rad5-initiated bypass mechanism, recruitment of Srs2 to SUMOylated PCNA causes sensitivity, as it prevents an alternative repair by HR. Deletion of *ELG1* suppresses the high sensitivity of *rad5Δ* mutants by delaying PCNA unloading, allowing more mono-ubiquitinated PCNA to remain on the chromatin, and thus enabling the recruitment of the Rev3 trans-lesion synthesis polymerase (Figure [8D](#F8){ref-type="fig"}).

![*elg1* mutants suppress *rad5*Δ MMS sensitivity. (**A**) Serial dilutions of yeast cultures on minimal SD-complete plates with or without MMS at the indicated concentrations show suppression of MK166 *rad5*Δ MMS sensitivity by all of the mutants except for *elg1-linker*. (**B**) Unmodified PCNA levels on the chromatin in the various *elg1* mutants in the *rad5*Δ background. (**C**) The RC in *rad5*Δ background does not correlate with the ability of the different *elg1* mutants to unload PCNA.](gkw1348fig7){#F7}

![*elg1*Δ suppression of *rad5*Δ MMS sensitivity depends on PCNA modifications. (**A**) Serial dilutions of yeast cultures on minimal SD-complete plates with or without MMS at the indicated concentrations show different sensitivities of *elg1* mutants to MMS in MK166 *pol30-RR rad5*Δ background. (**B**) An overexpression plasmid of *POL30, pol30-RR* or *pol30-164R* alleles was introduced into the indicated strains and the MMS sensitivity of these strains was tested. (**C**) A deletion of *REV3* abolishes the suppression effect of *elg1*Δ on *rad5*Δ MMS sensitivity. (**D**) A schematic representation of the model proposed: in wt cells the Elg1 RLC unloads PCNA from the DNA. This may take place during DNA repair or during DNA replication. Poly-ubiquitination of PCNA by Rad5 allows error-free repair. In the absence of *ELG1*, PCNA accumulates and becomes modified, mainly by SUMOylation. In *rad5Δ* cells, the error-free post-replication bypass mechanism triggered by PCNA poly-ubiquitination is eliminated, leading to sensitivity to DNA damage. In the absence of both *RAD5* and *ELG1* the TLS damage bypass pathway, mediated by PCNA mono ubiquitination and Rev3, can operate.](gkw1348fig8){#F8}

In conclusion, our work shows that modified and unmodified PCNA have a variety of roles in conferring genome stability and these roles are greatly affected by the activity of Elg1-RFC clamp unloader.
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